Pharmafile Logo
Pharmafocus logo
Advanced Search

Cosentyx

Showing 4 posts of 34 posts found.

novartis_window

NICE green-light for Novartis skin drug

May 29, 2015
Sales and Marketing Cosentyx, IL-17, NICE, Novartis, Secukinumab

NICE has released positive draft guidance for three treatments, including the first in a new generation of psoriasis drugs. Novartis’ …

News

Novartis and Abbott start year with strong Q1 sales

April 23, 2015
Sales and Marketing Abbott, Amgen, Cosentyx, GSK, Neupogen, Novartis, Secukinumab, Zarxio, biosimilar, filgrastim, financials

Novartis and Abbott have both posted strong first-quarter results and made bullish predictions about their financial performance in 2015. Novartis …

News

Pfizer, Novartis and Celgene among late-stage psoriasis trial advances

March 23, 2015
Sales and Marketing Celgene, Cosentyx, Enbrel, FDA, Novartis, Pfizer, otezla, psoriasis, tofacitinib

Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …

News
Novartis image

Novartis gets FDA approval for psoriasis drug

January 22, 2015
Sales and Marketing Cosentyx, European Commission, FDA, Novartis, Secukinumab, psoriasis

The US Food and Drug Administration (FDA) has shown Novartis’ skin condition drug Cosentyx the green light to treat patients …

News

Latest content

Circular Genomics reveals study results into predicting patient response to SSRI antidepressant treatment

May 8, 2024

Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib

May 7, 2024

Broken String Biosciences and the Francis Crick Institute collaborate on ALS research

May 7, 2024

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024